Drugs for Lobular Neoplasia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show all 37)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Tamoxifen |
Approved |
Phase 2, Phase 3 |
|
10540-29-1, 54965-24-1 |
2733526 |
Synonyms:
(Z)-2-(4-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylethanamine
(Z)-2-(Para-(1,2-diphenyl-1-butenyl)phenoxy)-N,N-dimethylamine
1-Para-b-dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
1-Para-beta-dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
1-Para-β-dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
1-p-b-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
1-p-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
1-p-Î’-dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
Apo-tamox
Citofen
Citrate, tamoxifen
Crisafeno
Diemon
EMBLON
FENTAMOX 10
FENTAMOX 20
Gen-tamoxifen
I.C.I.46474 CITRATE
ICI-46474
ICI-46474|Nolvadex®|Soltamox®
ICI-47699
Istubol
KENTADEX
KESSAR
KESSAR 10
KESSAR 20
Noltam
Nolvadex
NOLVADEX D
NOLVADEX FTE
Nolvadex-D
Nourytam
|
Novaldex
Novo-Tamoxifen
OESTRIFEN-10
OESTRIFEN-20
OESTRIFEN-40
Oncomox
PMS-Tamoxifen
Retaxim
Savient brand OF tamoxifen citrate
Soltamox
Tamizam
Tamofen
Tamone
Tamoplex
Tamoxasta
Tamoxen
TAMOXIFEN
Tamoxifen citrate
Tamoxifene
TAMOXIFÈNE
Tamoxifene [INN-French]
Tamoxifeno
Tamoxifeno [INN-Spanish]
Tamoxifenum
Tamoxifenum [INN-Latin]
Tomaxithen
trans-Tamoxifen
Valodex
ZD6157
Zemide
Zitazonium
ZYNOPLEX
|
|
2 |
|
Afimoxifene |
Investigational |
Phase 2, Phase 3 |
|
68392-35-8 |
63062 |
Synonyms:
4-(1-(4-(2-(Dimethylamino)ethoxy)phenyl)-2-phenylbut-1-enyl)phenol
4'-Hydroxytamoxifen
4-Hydroxytamoxifen
4-Hydroxy-tamoxifen
4-Hydroxytamoxifen, (e)-isomer
4-Hydroxytamoxifen, (Z)-isomer
4-Monohydroxytamoxifen
4-OHT
|
4-OHT hydrotamoxifen
4oh-Tamoxifen
AFIMOXIFENE
Hydroxytamoxifen
Monohydroxytamoxifen
Para-hydroxytamoxifen
TAMOGEL
Tamoxifen metabolite b
|
|
3 |
|
Antineoplastic Agents, Hormonal |
|
Phase 2, Phase 3 |
|
|
|
4 |
|
Estrogens |
|
Phase 2, Phase 3 |
|
|
|
5 |
|
Estrogen Receptor Modulators |
|
Phase 2, Phase 3 |
|
|
|
6 |
|
Estrogen Receptor Antagonists |
|
Phase 2, Phase 3 |
|
|
|
7 |
|
Estrogen Antagonists |
|
Phase 2, Phase 3 |
|
|
|
8 |
|
Hormones |
|
Phase 2, Phase 3 |
|
|
|
9 |
|
Hormone Antagonists |
|
Phase 2, Phase 3 |
|
|
|
10 |
|
Selective Estrogen Receptor Modulators |
|
Phase 2, Phase 3 |
|
|
|
11 |
|
Bevacizumab |
Approved, Investigational |
Phase 2 |
|
216974-75-3 |
135329020 |
Synonyms:
12-IGG1
ANTIVEGF
Anti-VEGF Humanized Monoclonal Antibody
Anti-VEGF monoclonal antibody
AVA-1
AVASTIN
Bevacizumab
BEVACIZUMAB BETA
bevacizumab-awwb
|
BI 695502
BS-503A
FKB-238
HLX04
HLX-04
R-435
RG-435
RHUMAB-
rhuMAb-VEGF
|
|
12 |
|
Epirubicin |
Approved |
Phase 2 |
|
56420-45-2 |
41867 |
Synonyms:
4' Epi adriamycin
4' Epi doxorubicin
4' Epi DXR
4' Epiadriamycin
4' Epidoxorubicin
4'-Epiadriamycin
4'-Epi-adriamycin
4'-Epidoxorubicin
4'-Epi-doxorubicin
4'-Epi-DXR
Cell pharm brand OF epirubicin
Ellence
EPI cell
Epiadriamycin
EPIcell
EPI-cell
Epidoxorubicin
Epi-Dx
Epilem
Epirubicin
Epirubicin hydrochloride
Epirubicina
Epirubicina [INN-Spanish]
Epirubicina [Spanish]
Epirubicine
|
Epirubicine [French]
Epirubicine [INN-French]
Epirubicinum
Epirubicinum [INN-Latin]
Epirubicinum [Latin]
Farmorubicin
Farmorubicina
Farmorubicine
Hydrochloride, epirubicin
IMI 28
IMI28
IMI-28
Kenfarma brand OF epirubicin hydrochloride
Lemery brand OF epirubicin hydrochloride
NSC-256942
Pfizer brand OF epirubicin hydrochloride
Pharmorubicin
Pharmorubicin Pfs
Pidorubicina
Pidorubicina [INN-Spanish]
Pidorubicine
Pidorubicine [INN-French]
Pidorubicinum
Pidorubicinum [INN-Latin]
Ridorubicin
|
|
13 |
|
Cyclophosphamide |
Approved, Investigational |
Phase 2 |
|
50-18-0, 6055-19-2 |
2907 |
Synonyms:
(+-)-Cyclophosphamide
(+,-)-2-(Bis(2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
(RS)-Cyclophosphamide
2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide
Anhydrous cyclophosphamide
Anhydrous, cyclophosphamide
ASTA
Asta B 518
Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester
Ciclofosfamida
Ciclofosfamide
Clafen
Claphene
CP
CPA
CTX
CY
Cyclophosphamid
Cyclophosphamide
Cyclophosphamide anhydrous
Cyclophosphamide monohydrate
Cyclophosphamide Sterile
Cyclophosphamide, (R)-isomer
Cyclophosphamide, (S)-isomer
Cyclophosphamidum
Cyclophosphan
Cyclophosphane
Cyclophosphoramide
|
Cyclostin
Cyklofosfamid
Cytophosphan
Cytophosphane
Cytoxan
Cytoxan Lyoph
Endoxan
Endoxan R
Endoxana
Endoxanal
Endoxan-Asta
Endoxane
Enduxan
Genoxal
Hexadrin
LEDOXINA
Lyophilized Cytoxan
Mitoxan
Monohydrate, cyclophosphamide
N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
Neosar
Procytox
Rcra Waste Number U058
Revimmune
Semdoxan
Sendoxan
Senduxan
Zyklophosphamid
|
|
14 |
|
Vinorelbine |
Approved, Investigational |
Phase 2 |
|
71486-22-1 |
44424639 60780 |
Synonyms:
5' Nor anhydrovinblastine
5'-Noranhydrovinblastine
5'-Nor-anhydrovinblastine
Navelbine
Navelbine Base
Vinorelbin
Vinorelbina
Vinorelbina [Spanish]
|
Vinorelbine
VINORELBINE BASE
Vinorelbine bitartrate
Vinorelbine ditartarate
Vinorelbine ditartrate
Vinorelbine tartrate
Vinorelbinum
Vinorelbinum [Latin]
|
|
15 |
|
Capecitabine |
Approved, Investigational |
Phase 2 |
|
154361-50-9 |
60953 |
Synonyms:
(1-(5-Deoxy-b-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamate pentyl ester
(1-(5-Deoxy-b-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamic acid pentyl ester
(1-(5-Deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamate pentyl ester
(1-(5-Deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamic acid pentyl ester
(1-(5-Deoxy-β-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamate pentyl ester
(1-(5-Deoxy-β-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamic acid pentyl ester
Capecitabin
Capecitabina
CAPECITABINE
Capécitabine
Capecitabinum
N(4)-Pentyloxycarbonyl-5'-deoxy-5-fluorocytidine
PENTYL [1-(3,4-DIHYDROXY-5-METHYL-OXOLAN-2-YL)-5-FLUORO-2-OXO-PYRIMIDIN-4-YL]AMINOFORMATE
Pentyl [1-(5-deoxy-b-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamate
Pentyl [1-(5-deoxy-b-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamic acid
Pentyl [1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamate
|
Pentyl [1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamic acid
Pentyl [1-(5-deoxy-β-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamate
Pentyl [1-(5-deoxy-β-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamic acid
Pentyl 1-(5-deoxy-b-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamate
Pentyl 1-(5-deoxy-b-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamic acid
Pentyl 1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamate
Pentyl 1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamic acid
Pentyl 1-(5-deoxy-β-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamate
Pentyl 1-(5-deoxy-β-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamic acid
R340
RO-091978000
RO-09-1978000
RO-09-1978-000
Ro-09-1978-000|Ro-091978000|Xeloda®
Xeloda
|
|
16 |
|
Trastuzumab |
Approved, Investigational |
Phase 2 |
|
180288-69-1 |
|
Synonyms:
4D5V8
ABP 980
ABP-980
ANTI HER2
D5v8|Herceptin®|R-597
DMB-3111 (TRASTUZUMAB BIOSIMILAR)
EG12014
EG-12014
HERCEPTIN
IG GAMMA-1 CHAIN C REGION
KADCYLA
|
R-597
RHUMAB HER2
SYD977
SYD-977
TRASTUZUMAB
TRASTUZUMAB BETA
trastuzumab-anns
trastuzumab-dkst
trastuzumab-dttb
trastuzumab-pkrb
trastuzumab-qyyp
|
|
17 |
|
Docetaxel |
Approved, Investigational |
Phase 2 |
|
114977-28-5 |
148124 |
Synonyms:
CKD-810
Docecad®|docetaxel anhydrous|EmDOC|Taxotere®
DOCEFREZ
DOCETAXEL
Docetaxel anhydrous
Docetaxel hydrate
Docetaxel trihydrate
Docetaxel, trihydrate
Docetaxol
N Debenzoyl N tert butoxycarbonyl 10 deacetyltaxol
|
N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel
N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol
N-Debenzoyl-N-tert-butoxycarbonyl-10-deacetyltaxol
NSC-628503
RP-56976
TAXCEUS
Taxoltere metro
Taxotere
TXL
XRP6976
|
|
18 |
|
Ethanol |
Approved |
Phase 2 |
|
64-17-5 |
702 |
Synonyms:
[CH2Me(OH)]
[OEtH]
1-Hydroxyethane
ABLYSINOL
Absolute alcohol
Absolute ethanol
Absolute ethyl alcohol
Aethanol
Aethylalkohol
Alcare hand degermer
Alcohol
Alcohol (ethyl)
Alcohol anhydrous
Alcohol denatured
ALCOHOL DETERMINATION--ALCOHOL
Alcohol etilico
Alcohol etílico
Alcohol, absolute
Alcohol, Dehydrated
Alcohol, denatured
ALCOHOL, DILUTED
Alcohol, ethyl
Alcohol, grain
ALCOHOL, RUBBING
Alcohols
Alcool ethylique
Alcool éthylique
Alcool etilico
Algrain
Alkohol
Alkoholu etylowego
Aminoethanol
Anhydrol
Anhydrous alcohol
Anhydrous ethanol
Äthanol
Äthylalkohol
B3324
Beta-Aminoethanol
Beta-Aminoethyl Alcohol
Beta-Ethanolamine
Beta-Hydroxyethylamine
C2H5OH
Caswell No. 426
Colamine
Cologne spirit
Cologne spirits
Dehydrated alcohol
Dehydrated ethanol
Denatured alcohol
Denatured Alcohol Cd-10
Denatured Alcohol Cd-5
Denatured Alcohol Cd-5a
Denatured Alcohol Sd-1
Denatured Alcohol Sd-13a
Denatured Alcohol Sd-17
Denatured Alcohol Sd-23a
Denatured Alcohol Sd-28
Denatured Alcohol Sd-30
Denatured Alcohol Sd-39b
Denatured Alcohol Sd-39c
Denatured Alcohol Sd-3a
Denatured Alcohol Sd-40m
Denatured ethanol
Desinfektol el
Diluted alcohol
Distilled spirits
DRINKING ALCOHOL
E1510
Envision Conditioner Pdd 9020
ETA
Etanol
|
Etanolo
ETHANOL
éthanol
Ethanol 200 proof
Ethanol Absolute
Ethanol Absolute Bp
Ethanol Anhydrous
Ethanol Extra Pure
Ethanol solution
Ethanol, Silent Spirit
Ethicap
Ethyl alc
Ethyl alcohol
Ethyl Alcohol & Water, 10%
Ethyl Alcohol & Water, 20%
Ethyl Alcohol & Water, 30%
Ethyl Alcohol & Water, 40%
Ethyl Alcohol & Water, 5%
Ethyl Alcohol & Water, 50%
Ethyl Alcohol & Water, 60%
Ethyl Alcohol & Water, 70%
Ethyl Alcohol & Water, 80%
Ethyl Alcohol & Water, 95%
Ethyl Alcohol & Water, 96%
Ethyl alcohol anhydrous
Ethyl alcohol in alcoholic beverages
Ethyl alcohol usp
Ethyl Alcohol, Anhydrous
Ethyl Alcohol, Denatured
Ethyl hydrate
Ethyl hydroxide
Ethylol
Ethylolamine
EtOH
FEMA NO. 2419
Fermentation alcohol
Glycinol
Grain alcohol
Hinetoless
HSDB 531
Hydroxyethane
Infinity pure
Jaysol
Jaysol S
Lux
METHYLATED MINERAL
Methylated Spirit Mineralised
Methylcarbinol
Molasses alcohol
NCI-C03134
NSC-85228
PM-6193-200
Potato alcohol
Punctilious ethyl alcohol
Pyro
Reagent Alcohol
Silent spirit
SPIRIGEL
Spirit
Spirits OF wine
Spiritus vini
Spirt
SURG
Synasol
Tecsol
Tecsol C
Thanol
Thiofaco M-50
Undenatured ethanol
USAF EK-1597
VODKA
|
|
19 |
|
Naltrexone |
Approved, Investigational, Vet_approved |
Phase 2 |
|
16590-41-3 |
5360515 |
Synonyms:
(-)NALTREXONE
(-)naltrexone|naltrexone HCl|ReVia®
17-(Cyclopropylmethyl)-4,5a-epoxy-3,14-dihydroxymorphinan-6-one
17-(Cyclopropylmethyl)-4,5alpha-epoxy-3,14-dihydroxymorphinan-6-one
17-(Cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinan-6-one
17-(Cyclopropylmethyl)-4,5α-epoxy-3,14-dihydroxymorphinan-6-one
Antaxone
Bristol myers squibb brand OF naltrexone hydrochloride
Bristol-myers squibb brand OF naltrexone hydrochloride
Celupan
Du pont brand OF naltrexone hydrochloride
EN-1639A
EN-1639A [AS HYDROCHLORIDE]
EN-1639A FREE BASE
Hydrochloride, naltrexone
Lacer brand OF naltrexone hydrochloride
Lamepro brand OF naltrexone hydrochloride
MorViva
Nalorex
Naltrexon
Naltrexona
|
Naltrexona [INN-Spanish]
Naltrexone
Naltrexone [Usan:Ban:Inn]
NALTREXONE HCL
Naltrexone hydrochloride
Naltrexonum
Naltrexonum [INN-Latin]
N-Cyclopropylmethyl-14-hydroxydihydromorphinone
N-Cyclopropylmethylnoroxymorphone
Nemexin
Orphan brand OF naltrexone hydrochloride
Pharmazam brand OF naltrexone hydrochloride
PTI-555
ReVia
Schering plough brand OF naltrexone hydrochloride
Schering-plough brand OF naltrexone hydrochloride
TREXAL
Trexan
United drug brand OF naltrexone hydrochloride
Vivitrex
Vivitrol
|
|
20 |
|
Anti-Bacterial Agents |
|
Phase 2 |
|
|
|
21 |
|
Alkylating Agents |
|
Phase 2 |
|
|
|
22 |
|
Antirheumatic Agents |
|
Phase 2 |
|
|
|
23 |
|
Antineoplastic Agents, Alkylating |
|
Phase 2 |
|
|
|
24 |
|
Antimitotic Agents |
|
Phase 2 |
|
|
|
25 |
|
Angiogenesis Inhibitors |
|
Phase 2 |
|
|
|
26 |
|
Antimetabolites |
|
Phase 2 |
|
|
|
27 |
|
Tubulin Modulators |
|
Phase 2 |
|
|
|
28 |
|
Antibiotics, Antitubercular |
|
Phase 2 |
|
|
|
29 |
|
Antineoplastic Agents, Immunological |
|
Phase 2 |
|
|
|
30 |
|
Immunosuppressive Agents |
|
Phase 2 |
|
|
|
31 |
|
Immunologic Factors |
|
Phase 2 |
|
|
|
32 |
|
Narcotic Antagonists |
|
Phase 2 |
|
|
|
33 |
|
Narcotics |
|
Phase 2 |
|
|
|
34 |
|
Pasireotide |
Approved |
Phase 1 |
|
396091-73-9 |
56841596 9941444 |
Synonyms:
cyclo((4R)-4-(2-aminoethylcarbamoyloxy)-L-prolyl-L-phenylglycyl-D-tryptophyl-L-lysyl-4-O-benzyl-L-tyrosyl-L- phenylalanyl-)
Pasireotida
Pasireotide
Pasiréotide
pasireotide diaspartate|Signifor®|SOM 230|SOM 320|SOM-230
|
Pasireotidum
SIGNIFOR
SOM 230
SOM230
SOM-230
|
|
35 |
|
Bexarotene |
Approved, Investigational |
Phase 1 |
|
153559-49-0 |
82146 |
Synonyms:
3-Methyl-ttneb
4-(1-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethenyl)benzoic acid
4-[1-(3,5,5,8,8-PENTAMETHYLTETRALIN-2-YL)ETHENYL]BENZOIC ACID
4-[1-(5,6,7,8,-TETRAHYDRO-3,5,5,8,8-PENTAMETHYL-2-NAPHTALENYL)ETHENYL]BENZOIC ACID
BEXAROTEN
BEXAROTENE
BEXAROTÈNE
Bexaroteno
Bexarotenum
Elan brand OF bexarotene
LG100069
LG-100069
|
LG69 Compound
LGD1069
LGD-1069
LGD1069|Targretin®|Targrexin®
Ligand brand OF bexarotene
p-(1-(5,6,7,8-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphthyl)vinyl)benzoate
p-(1-(5,6,7,8-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphthyl)vinyl)benzoic acid
P-[1-(5,6,7,8,-TETRAHYDRO-3,5,5,8,8-PENTAMETHYL-2-NAPHTHYL)VINYL]BENZOIC ACID
Targretin
TARGRETINE
TARGRETYN
TARGREXIN
|
|
36 |
|
Zinc cation |
Approved, Experimental, Investigational |
|
|
7440-66-6, 23713-49-7 |
32051 |
Synonyms:
alpha D Mannosidase
alpha D Mannoside mannohydrolase
alpha Mannosidase
alpha Mannosidase b
alpha-D-Mannosidase
alpha-D-Mannoside mannohydrolase
alpha-Mannosidase
alpha-Mannosidase, lysosomal
alpha-Mannosidase, neutral
Dietary zinc
LAMAN
Lysosomal alpha mannosidase
Lysosomal alpha-mannosidase
Mannohydrolase, alpha-D-mannoside
Mannosidase b, alpha
Neutral alpha mannosidase
|
Neutral alpha-mannosidase
Topostin b
Zinc cation
ZINC ion
Zinc ion(2+)
Zinc(2+)
Zinc(II)
Zinc, chelated
Zinc, elemental
Zinc, ion (ZN2+)
zinc|zinc ion
Zincum metallicum
Zn
ZN(2+)
ZN(II)
ZN2+
|
|
37 |
|
Iodine |
Approved, Investigational |
|
|
7553-56-2 |
807 |
Synonyms:
Cadex
Diiodine
I2
Iode
Iodine
Iodine 127
Iodine-127
Iodine-molecule
|
Iodio
iodo
Iodum
Jod
Jood
Molecular iodine
NSC-42355
Tincture iodine
|
|
Interventional clinical trials:
(show all 20)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
A Phase IIB Randomized Trial of Oral Tamoxifen vs. Topical 4-hydroxytamoxifen Gel vs. Control in Women With Atypical Hyperplasia or Lobular Carcinoma In Situ |
Suspended |
NCT04570956 |
Phase 2, Phase 3 |
Tamoxifen;Topical 4-OHT( 4-hydroxytamoxifen)gel 2 mg/each breast/day;Placebo |
2 |
"Phase II Study of PET Guided Neoadjuvant Chemotherapy (NAC) and Oncotype Guided Hormonal Therapy of Breast Cancer" |
Unknown status |
NCT01641406 |
Phase 2 |
Docetaxel, Epirubicin, Cyclophosphamide/Navelbine, Capecitabine, Trastuzumab, Bevacizumab |
3 |
Window Trial of Abemaciclib for Surgically Resectable, Chemotherapy-Resistant, Triple Negative Breast Cancer (a BEAUTY Study*) |
Recruiting |
NCT03979508 |
Phase 2 |
Abemaciclib |
4 |
TBCRC 042 - A Randomized Phase II Window-of-Opportunity Trial of Ruxolitinib in Patients With High Risk and Premalignant Breast Conditions |
Recruiting |
NCT02928978 |
Phase 2 |
Ruxolitinib;Placebo (for Ruxolitinib) |
5 |
A Phase II Study of Accelerated 3 Fraction Photon and Proton Partial Breast External Beam Radiotherapy and Partial Breast Brachytherapy for Early Invasive and Noninvasive Breast Cancer |
Active, not recruiting |
NCT03391388 |
Phase 2 |
|
6 |
Naltrexone Randomized Controlled Trial for Treatment-Emergent Fatigue in Patients Receiving Radiation Therapy for Breast Cancer |
Terminated |
NCT02137252 |
Phase 2 |
Naltrexone;Sugar Pill |
7 |
Breast Cancer Chemoprevention by SOM230, an IGF-I Action Inhibitor: A Proof of Principle Trial |
Completed |
NCT01372644 |
Phase 1 |
SOM 230 / Pasireotide |
8 |
Phase I Trial of Endoxifen Gel Versus Placebo Gel in Women Undergoing Breast Surgery |
Active, not recruiting |
NCT03317405 |
Phase 1 |
Endoxifen Hydrochloride |
9 |
A Phase I Dose Escalation Study of Topical Bexarotene in Women at High Risk for Breast Cancer |
Active, not recruiting |
NCT03323658 |
Phase 1 |
Bexarotene |
10 |
GLACIER: A Study to Investigate the Genetics of LobulAr Carcinoma In Situ in EuRope |
Unknown status |
NCT00536718 |
|
|
11 |
The Incidence of Adjacent Synchronous Ipsilateral Infiltrating Carcinoma, DCIS, or Atypical Ductal Hyperplasia (ADH) in Patients Diagnosed With Lobular Neoplasia of the Breast by Core Needle Biopsy |
Completed |
NCT00146536 |
|
|
12 |
Management of Ductal Carcinoma in Situ (DCIS) or Pure Micro-invasive (DCIS-MI) Extended Breast, Axillary Node Sentinel Site (GAS) When the Diagnosis is Made by Biopsy and Treatment by Mastectomy Immediately. Descriptive Study |
Completed |
NCT01841749 |
|
|
13 |
Evaluation of a Small Field of View Gamma Camera for Scintimammography in Patients With Atypical Ductal Hyperplasia, Atypical Lobular Hyperplasia, and Lobular Carcinoma In Situ |
Completed |
NCT00620087 |
|
|
14 |
Molecular Genetic Basis of Invasive Breast Cancer Risk Associated With Lobular Carcinoma in Situ |
Completed |
NCT00581750 |
|
|
15 |
Cool Down With EMBr: Enhancing Menopausal Hot Flash Symptom Reduction After Breast Cancer |
Recruiting |
NCT05086705 |
|
|
16 |
Improving Well-Being for Individuals With Persistent Pain After Surgery for Breast Cancer, Lobular Carcinoma in Situ, or Ductal Carcinoma in Situ: A Randomized Clinical Trial That Compares Three Behavioral Intervention Strategies and Examines Psychological Factors as Drivers of the Continuing Burden of Persistent Pain |
Recruiting |
NCT04225585 |
|
|
17 |
Cluster Randomized Controlled Trial of Patient and Provider Decision Support to Increase Chemoprevention Informed Choice Among Women With Atypical Hyperplasia or Lobular Carcinoma In Situ - Making Informed Choices on Incorporating Chemoprevention Into Care (MiChoice) |
Recruiting |
NCT04496739 |
|
|
18 |
Energy Balance and Breast Cancer Aspects-II Study |
Active, not recruiting |
NCT02240836 |
|
|
19 |
Efficacy, Safety, Cosmesis and Patient Satisfaction With Vacuum-Assisted Percutaneous Excision (VAPE) Compared With Standard Surgical Excision (X) of Non-malignant, Borderline or High-risk Breast Lesions: A Randomized Controlled Trial |
Not yet recruiting |
NCT03868475 |
|
|
20 |
Longitudinal Study Evaluating the Impact of Dietary Inflammatory Potential on Breast Cancer Risk in a Cohort of Women Followed in the Breast Cancer Prevention Clinic at the Ohio State University Comprehensive Cancer Center- James Cancer Hospital and Solove Research Institute |
Not yet recruiting |
NCT05178498 |
|
|
|